Prostate Cancer Treatment - Global Strategic Business Report

The global market for Prostate Cancer Treatment was estimated at US$21.4 Billion in 2024 and is projected to reach US$31.2 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Prostate Cancer Treatment market.

Global Prostate Cancer Treatment Market - Key Trends & Drivers Summarized

Why Is Prostate Cancer Treatment Experiencing a Shift Toward Personalized and Targeted Therapies?

The prostate cancer treatment market is undergoing a major transformation with the rise of personalized medicine and precision oncology. Prostate cancer, one of the most commonly diagnosed malignancies among men worldwide, has seen expanded treatment options beyond traditional surgery and radiation. New frontiers in immunotherapy, androgen receptor pathway inhibitors, radioligand therapy, and next-generation anti-androgens are now redefining therapeutic paradigms. These developments are being driven by increasing understanding of genetic mutations, hormone responsiveness, and tumor microenvironments that impact disease progression.

Targeted therapies such as PARP inhibitors (e.g., olaparib and rucaparib) are gaining traction among patients with BRCA1/2 or other homologous recombination repair (HRR) gene mutations. These drugs selectively inhibit DNA repair in cancer cells, offering significant clinical benefits in metastatic castration-resistant prostate cancer (mCRPC). Additionally, precision diagnostics like next-generation sequencing (NGS) and liquid biopsy are being used to profile tumor genomics, enabling oncologists to tailor treatment based on molecular signatures. This shift toward genomic-informed decision-making is central to improving survival rates and reducing overtreatment in low-risk patients.

Which Treatment Modalities and Patient Segments Are Reshaping the Market Landscape?

Historically, prostate cancer management relied on surgery (radical prostatectomy), radiation therapy (external beam or brachytherapy), and androgen deprivation therapy (ADT). While these continue to be foundational interventions, the rise in advanced-stage diagnoses and the emergence of hormone-resistant tumors have intensified demand for more sophisticated systemic therapies. In high-risk and metastatic settings, the combination of ADT with next-generation androgen receptor inhibitors such as enzalutamide, apalutamide, and darolutamide has become the new standard of care.

Older patients with comorbidities or low-grade disease increasingly benefit from active surveillance programs, reducing unnecessary exposure to invasive therapies. Conversely, patients with mCRPC are now candidates for radioligand therapies like Lutetium-177-PSMA-617, which deliver targeted radiation to prostate-specific membrane antigen (PSMA)-positive cells. Immunotherapeutics such as sipuleucel-T (Provenge) represent the first wave of cancer vaccines, although adoption remains limited due to logistical complexity and modest efficacy. The patient population is becoming more segmented based on risk stratification, tumor biology, and prior treatment exposure-guiding clinicians toward multi-modal, stage-specific interventions.

How Are Technology, Drug Development, and Regulatory Dynamics Influencing Treatment Access and Innovation?

Innovation in prostate cancer treatment is accelerating due to a robust drug development pipeline and a supportive regulatory environment. Agencies like the U.S. FDA and European Medicines Agency (EMA) have granted priority review and breakthrough designations for several novel therapies, especially those targeting genetic biomarkers. Companies are also leveraging real-world evidence (RWE) and adaptive trial designs to fast-track approvals and post-marketing surveillance. Companion diagnostics are increasingly co-developed with therapies to ensure optimal patient selection, minimizing toxicity and cost inefficiencies.

Advances in robotic-assisted surgery (e.g., Da Vinci systems), intensity-modulated radiation therapy (IMRT), and image-guided brachytherapy are improving treatment precision while minimizing adverse effects. AI-enabled platforms are now being deployed for treatment planning, pathology image interpretation, and progression prediction. Additionally, the integration of telemedicine for follow-ups and PSA monitoring is enhancing continuity of care, especially in rural or underserved regions. Cost remains a barrier in low- and middle-income countries, though international cancer consortia and global access programs are attempting to bridge the therapeutic equity gap.

What Factors Are Driving the Growth of the Global Prostate Cancer Treatment Market?

The growth in the global prostate cancer treatment market is driven by the aging male population, rising incidence of prostate cancer diagnoses, expanding biomarker-driven therapies, and increased payer support for advanced interventions. Improved public awareness and expanded screening programs, particularly in developed regions, are leading to earlier diagnosis and better patient outcomes. Simultaneously, the rising global prevalence of late-stage or aggressive prostate cancer is necessitating the adoption of novel drug classes and precision radiation methods.

Biopharmaceutical innovation is another key growth driver. Several next-generation agents targeting AR-V7 splice variants, PI3K/AKT/mTOR pathways, and DNA damage repair mechanisms are in late-phase clinical development. Partnerships between pharmaceutical companies and diagnostics firms are accelerating market entry of targeted therapies with robust reimbursement frameworks. Emerging markets such as China, Brazil, and India are also witnessing faster regulatory approvals and market access, backed by national cancer control policies and expanded oncology infrastructure.

Key players in the market include Johnson & Johnson (Janssen), Pfizer Inc., Astellas Pharma, Bayer AG, Novartis AG, AstraZeneca, and Telix Pharmaceuticals. These firms are investing in clinical trials, molecular diagnostic tools, and strategic acquisitions to strengthen their prostate oncology portfolios. As treatment approaches shift toward chronic disease management and individualized care, the global market is set to expand across surgical, pharmaceutical, and radiotherapeutic domains.

Scope Of Study:

The report analyzes the Prostate Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Therapy Type (Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy, Immunotherapy); End-Use (Hospitals End-Use, Clinics End-Use)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Prostate Surgery segment, which is expected to reach US$9.5 Billion by 2030 with a CAGR of a 8.3%. The Radiation Therapy segment is also set to grow at 7.3% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $5.8 Billion in 2024, and China, forecasted to grow at an impressive 10.5% CAGR to reach $6.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Prostate Cancer Treatment Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Prostate Cancer Treatment Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Prostate Cancer Treatment Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Prostate Cancer Treatment market report include:

• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Dendreon Pharmaceuticals LLC
• Eli Lilly and Company
• Exelixis Inc.
• F. Hoffmann-La Roche AG
• Ferring Pharmaceuticals Inc.
• Fusion Pharmaceuticals Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Myovant Sciences GmbH
• Novartis AG
• Pfizer Inc.
• Point Biopharma
• Sanofi S.A.
• Santen Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals (Bausch)

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.